Family-owned Boehringer Ingelheim is bracing for a rough 2014. The drugmaker indicated in its 2013 annual report that “we can expect to face challenges,” and that it is not expecting BI, let alone the industry, to experience a significant upswing within the next 12 months. This was not the German company’s only downbeat news: BI has also indicated it has stepped out of the interferon-free Hepatitis C race.
Help employers find you! Check out all the jobs and post your resume.
